Featured Research

from universities, journals, and other organizations

Weizmann Institute Scientists Block Loss Of Eyesight In Animals With A Glaucoma-Like Disease

Date:
March 8, 2001
Source:
Weizmann Institute
Summary:
Weizmann Institute scientists have succeeded in stopping the progressive loss of eyesight in animals with a glaucoma-like disease. Their innovative study, reported in the March 6, 2001 issue of the Proceedings of the National Academy of Sciences U.S.A., suggests that Copaxone, a drug developed at the Weizmann Institute of Science to treat multiple sclerosis, may also stop, or at least slow down, the loss of eyesight in people with chronic glaucoma.

Weizmann Institute scientists have succeeded in stopping the progressive loss of eyesight in animals with a glaucoma-like disease. Their innovative study, reported in the March 6, 2001 issue of the Proceedings of the National Academy of Sciences U.S.A., suggests that Copaxone, a drug developed at the Weizmann Institute of Science to treat multiple sclerosis, may also stop, or at least slow down, the loss of eyesight in people with chronic glaucoma.

Glaucoma, which affects 1 percent of the adult population, is the main cause of blindness in adults. The majority of patients with chronic glaucoma have increased pressure inside the eye due to defective drainage of the transparent fluid that bathes the eye and nourishes its outer cells. The increase in this intraocular pressure (IOP) damages the optic nerve, causing it to degenerate and often leading to loss of eyesight.

For many years, the search for improved glaucoma therapies focused on correcting the eye’s drainage system to reduce IOP. Eventually, however, it became clear that reducing the pressure was not enough to halt the ongoing degeneration of the optic nerve and did not eliminate the risk of blindness. Scientists concluded that a crucial factor was being overlooked and they set out in search of this missing link.

Approximately five years ago, Prof. Michal Schwartz of the Weizmann Institute’s Neurobiology Department proposed a new concept to account for the continuing degeneration of the optic nerve that occurs after the pressure in the eye had been reduced. Schwartz suggested that while the initial damage to the optic nerve is indeed caused by increased eye pressure, secondary factors triggered by the initial damage contribute to the nerve's ongoing degeneration.

The offending factors include chemicals that play an important role in the life of a healthy nerve, but when the nerve degenerates, their concentrations increase to a toxic level. One of these chemicals is the neurotransmitter glutamate, which spills from damaged nerve cells and adversely affects healthy neighboring cells.

In line with this concept, Prof. Schwartz developed an original strategy for tackling the problem. To protect the nerve from harmful substances coming from the body itself, she recruited the immune system, whose well-known role is to defend the body against outside “invaders.” This approach at first raised a few eyebrows, mainly because it involved cells that, when activated, usually cause one of the autoimmune diseases in which the body mistakenly attacks itself, such as juvenile diabetes or multiple sclerosis. The concept of using these "enemy" cells to heal the body seemed uncanny.

Prof. Schwartz, who has also developed an immune-based therapy for spinal cord injuries now being tested in a clinical trial, believes that—contrary to accepted wisdom—autoimmunity can play a beneficial role in the body. A series of studies in her lab has shown that immunization with fragments of proteins belonging to myelin, the protective sheath of the nerves, can prevent degeneration of the damaged optic nerve.

However, the use of such protein fragments, or peptides, for immunizing people is fraught with risk because some of these peptides cause the immune system to attack nerve fibers, leading to multiple sclerosis. Since humans vary greatly in their genetic makeup, it is difficult to establish which of the peptides would cause disease in a specific patient.

Looking for a safe alternative to these peptides, Schwartz and her group, in collaboration with Profs. Irun Cohen and Michael Sela of the Weizmann Institute's Immunology Department, demonstrated that immunization with Copaxone, a synthetic compound that reacts with cells that respond to self-proteins, protects the damaged optic nerve from neuronal degeneration.

Copaxone was developed at the Institute by Dr. Dvora Teitelbaum, Prof. Ruth Arnon and Prof. Michael Sela as a drug for multiple sclerosis.

In the present study, the scientists sought to establish how Copaxone produces its protective effect on the nerve. This research -- conducted by Prof. Schwartz, Dr. Eti Yoles and graduate students Jonathan Kipnis and Hadas Schori -- showed that immunization with Copaxone shields the nerve from the toxic effects of the neurotransmitter glutamate. These findings strongly suggest that Copaxone immunization is a potential therapy for glaucoma, in which the optic nerve undergoes degeneration and glutamate levels rise.

Indeed, in another series of experiments conducted together with scientists from the U.S. company Allergan, Inc. (who developed the rat model that simulates chronic glaucoma), Copaxone immunization proved even more effective. In rats immunized with a single injection of Copaxone, only about 4 percent of nerve cells died in the glaucoma-affected eye, compared with 28 percent in rats that were not immunized. Thus, immunization with Copaxone dramatically protected the nerve from pressure-induced death.

Following the success of this research, trials in human patients with glaucoma are expected to begin soon. Scientists hope that the trials will be facilitated by the fact that the U.S. Food and Drug Administration has already approved Copaxone.

Prof. Michal Schwartz holds the Maurice and Ilse Katz Chair of Neuroimmunology. Her research is supported by the Alan T. Brown Foundation to Cure Paralysis, the Glaucoma Research Foundation and the Jerome and Binette Lipper Award.

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world’s foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of humanity. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities at Weizmann.


Story Source:

The above story is based on materials provided by Weizmann Institute. Note: Materials may be edited for content and length.


Cite This Page:

Weizmann Institute. "Weizmann Institute Scientists Block Loss Of Eyesight In Animals With A Glaucoma-Like Disease." ScienceDaily. ScienceDaily, 8 March 2001. <www.sciencedaily.com/releases/2001/03/010307071149.htm>.
Weizmann Institute. (2001, March 8). Weizmann Institute Scientists Block Loss Of Eyesight In Animals With A Glaucoma-Like Disease. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2001/03/010307071149.htm
Weizmann Institute. "Weizmann Institute Scientists Block Loss Of Eyesight In Animals With A Glaucoma-Like Disease." ScienceDaily. www.sciencedaily.com/releases/2001/03/010307071149.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins